OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 Cold peptides
  2. 2 peptides for common colds or flu

Answered on this page ↓

peptides for common colds or flu

Nov 16, 2026 · 7 sources used · OpenNeedle synthesis
No peptide has been shown to prevent or treat a common cold or flu in people. The flu peptide work is all cells and mice.

The most developed flu peptide is 12B, an engineered amyloid that binds the influenza A PB2 protein. In cells it cut viral plaques by about 80% at 10 µM, with an IC50 near 1.79 µM [1]. In mice given 2.5 mg/kg intravenously for six days, it produced only a small reduction in lung virus versus buffer and Tamiflu [1]. It does nothing against influenza B [1]. That is a long way from a cold remedy.

PeptideModelResultHuman data
12B (anti-PB2)Cells, mice [1]~80% plaque cut; small mouse titer drop [1]None
P10/P24 (mRNA-encoded)Cells only [5]~1000-fold titer cut in A549 [5]None
FluPep / super FluPepCells only [3]IC50 down to 0.09 nM [3]None
Cyclic peptides vs HACells only [2]Binding ~10-15 nM [2]None
3L11 antibodyMice [4]100% survival at 30 mg/kg [4]None

For colds, the peptide-adjacent work is a rhinovirus 3C protease structure used to design inhibitors [7], and a soluble ICAM-1 decoy (Tremacamra) that cut symptoms about 45% and colds about 23% in experimental infection [6]. Tremacamra is a protein, not a peptide you can buy, and it was tested in volunteers deliberately infected, not in natural colds.

Nothing here is a product. The cell and mouse numbers are mechanism, not proof for a person. No trial in this set gave a peptide to people with a cold or flu and measured whether they got better.

My call: skip peptide cold and flu products; the human evidence does not exist. Confidence: moderate.

Keep digging

Sources used 7

  1. Reverse engineering synthetic antiviral amyloids Nature Communications (2020) Thin

    Engineered APR-based synthetic amyloids selectively bind viral proteins to trigger targeted aggregation, inhibiting influenza A PB2–dependent replication in cells and in vivo, with APR-specific activity that extends to ZIKV and shows no effect on influenza B.

    DOI: 10.1038/s41467-020-16721-8
  2. An ultrasound bioprobe for biological imaging Science (2017) Thin

    Kadam et al. developed small cyclic peptides that mimic broadly neutralizing antibodies to hemagglutinin, effectively blocking influenza virus entry into cells and demonstrating potential as a new class of antiviral drugs.

    DOI: 10.1126/science.358.6362.493-m
  3. The potent anti-influenza virus activity of FluPep is mediated by interactions with cellular anionic polysaccharides primary study Strong

    FluPep's anti-influenza virus activity is mediated by binding to cellular heparan sulfate and sialic-acid glycans, not to virus particles; replacing its RRKK tract with growth-factor heparin-binding sequences increases potency.

    DOI: 10.64898/2026.09.15.751766
  4. Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient Antiviral Research (2019) primary study Strong

    3L11 neutralizes H7N9 in vitro and fully protects mice in vivo; epitope near the 150-loop; escape mutations G151R/S152P disrupt binding; Fc-mediated ADCC likely contributes to in vivo protection.

    DOI: 10.1016/j.antiviral.2019.104564
  5. Affinity-enhanced peptides delivered by mRNA–LNPs inhibit influenza A virus replication by disrupting the PA-PB1 interaction primary study Strong

    mRNA-LNP-encoded affinity-enhanced PB1-derived peptides P10 and P24 inhibit influenza A virus replication in cultured cells by disrupting the PA-PB1 polymerase interaction.

    DOI: 10.64898/2026.07.29.740963
  6. Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection JAMA (1999) Thin

    This study evaluates the efficacy of Tremacamra, a soluble intercellular adhesion molecule 1, in reducing symptoms and viral load in experimental rhinovirus infections through four randomized clinical trials.

    DOI: 10.1001/jama.281.19.1797
  7. NMR Solution Structures of the Apo and Peptide-Inhibited Human Rhinovirus 3C Protease (Serotype 14): Structural and Dynamic Comparison Biochemistry (2007) Thin

    This study presents the NMR solution structures of the apo and peptide-inhibited forms of the human rhinovirus 3C protease (HRV14), revealing significant structural and dynamic differences that inform the design of effective protease inhibitors.

    DOI: 10.1021/bi7010866

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →